Pharmaniaga Berhad Statistics

Total Valuation

KLSE:PHARMA has a market cap or net worth of MYR 367.51 million. The enterprise value is 1.56 billion.

Market Cap	367.51M
Enterprise Value	1.56B

Important Dates

The next estimated earnings date is Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	n/a

Share Statistics

KLSE:PHARMA has 1.44 billion shares outstanding. The number of shares has increased by 8.00% in one year.

Current Share Class	n/a
Shares Outstanding	1.44B
Shares Change (YoY)	+8.00%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	4.19%
Owned by Institutions (%)	10.83%
Float	488.58M

Valuation Ratios

The trailing PE ratio is 3.91 and the forward PE ratio is 7.97.

PE Ratio	3.91
Forward PE	7.97
PS Ratio	0.10
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.39, with an EV/FCF ratio of -20.83.

EV / Earnings	16.64
EV / Sales	0.43
EV / EBITDA	6.39
EV / EBIT	7.52
EV / FCF	-20.83

Financial Position

The company has a current ratio of 0.63

Current Ratio	0.63
Quick Ratio	0.34
Debt / Equity	n/a
Debt / EBITDA	5.06
Debt / FCF	-16.49
Interest Coverage	2.97

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	6.33%
Return on Invested Capital (ROIC)	13.07%
Return on Capital Employed (ROCE)	2,561.27%
Revenue Per Employee	1.04M
Profits Per Employee	27,056
Employee Count	3,476
Asset Turnover	1.76
Inventory Turnover	5.36

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -36.25% in the last 52 weeks. The beta is 1.45, so KLSE:PHARMA's price volatility has been higher than the market average.

Beta (5Y)	1.45
52-Week Price Change	-36.25%
50-Day Moving Average	0.34
200-Day Moving Average	0.37
Relative Strength Index (RSI)	16.11
Average Volume (20 Days)	1,880,430

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KLSE:PHARMA had revenue of MYR 3.62 billion and earned 94.05 million in profits. Earnings per share was 0.07.

Revenue	3.62B
Gross Profit	440.76M
Operating Income	208.13M
Pretax Income	143.42M
Net Income	94.05M
EBITDA	233.94M
EBIT	208.13M
Earnings Per Share (EPS)	0.07

Full Income Statement

Balance Sheet

The company has 66.43 million in cash and 1.24 billion in debt, giving a net cash position of -1.17 billion or -0.81 per share.

Cash & Cash Equivalents	66.43M
Total Debt	1.24B
Net Cash	-1.17B
Net Cash Per Share	-0.81
Equity (Book Value)	-150.17M
Book Value Per Share	-0.12
Working Capital	-797.24M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -33.14 million and capital expenditures -41.99 million, giving a free cash flow of -75.13 million.

Operating Cash Flow	-33.14M
Capital Expenditures	-41.99M
Free Cash Flow	-75.13M
FCF Per Share	-0.05

Full Cash Flow Statement

Margins

Gross margin is 12.17%, with operating and profit margins of 5.74% and 2.60%.

Gross Margin	12.17%
Operating Margin	5.74%
Pretax Margin	3.96%
Profit Margin	2.60%
EBITDA Margin	6.46%
EBIT Margin	5.74%
FCF Margin	n/a

Dividends & Yields

KLSE:PHARMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.00%
Shareholder Yield	-8.00%
Earnings Yield	25.59%
FCF Yield	-20.44%

Dividend Details

Stock Splits

The last stock split was on July 5, 2021. It was a forward split with a ratio of 5.

Last Split Date	Jul 5, 2021
Split Type	Forward
Split Ratio	5

Scores

KLSE:PHARMA has an Altman Z-Score of 1.4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.4
Piotroski F-Score	n/a